Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France

Conditions

• Chronic Rhinosinusitis With Nasal Polyposis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Dupilumab — DRUG
  This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.

Study Details

This is a multicentre, non-interventional, single arm study that aims to describe the treatment patterns in France: patients' characteristics, disease characteristics, prior treatments for Severe chronic rhinosinusitis with nasal polyposis and treatment prescription modalities. As well as to assess the clinical outcome after initiation of dupilumab (Dupixent®) and safety of the product during the two years of treatment

Key Dates

Start date

Oct 20, 2023

Status verified

Jun 2026

Primary completion

Jul 31, 2026

Completion

Jul 31, 2026

Study Design

Enrollment

150 participants (estimated)

Arms

• Arm: Dupilumab
  The information will be collected during consultation as part of the patient's usual follow-up.

Primary Outcome Measure

Patient characteristics: Age [ Time Frame: At baseline (Day 1) ]